pharma news today obesity drugs glp-1 october 2025 Market Overview: Agonists and the Market | Blog The world is desperate for

10.18632/aging.102899 145 XiongX.-Q.GengZ.ZhouB.ZhangF.HanY.ZhouY.-B.et al (2018)

Importantly, while weight loss represents a major contributor to the clinical benefits of GLP-1RAs, accumulating evidence indicates that these agents also exert non-weight-dependent effects

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Kim W., Barhoumi R., McMurray D.N., Chapkin R.S

Existing studies have only confirmed two key findings: first, milk and plant-derived proteins can reduce the incidence of depression (29)

Intravenous therapy may be considered under medical supervision for specific health conditions, but it carries more risks and is not recommended for cosmetic purposes by most experts

Major corporations are tapping into the lucrative weight loss drug market, which is anticipated to grow from $6 billion to $100 billion by 2030, per Goldman Sachs